2005 Press Releases

Allergan and Inamed Execute Definitive Merger Agreement  

Allergan Extends Expiration Date of Exchange Offer for Inamed Corporation  

Allergan Requests Temporary Restraining Order and Preliminary Injunction in ACULAR(R) Patent Infringement Case; Seeks Ban on Sale of Proposed Generic Drug Pending Court Ruling  

Allergan Welcomes Inamed's Recommendation of Its Offer to Stockholders; Parties Look to Execute Merger Agreement and Close Transaction  

Allergan Completes Negotiation of Terms and Conditions of Merger Agreement with Inamed and Inamed Board of Directors Has Concluded that Allergan's Offer is Superior  

Allergan, Inc. Commences Exchange Offer for Shares of Inamed Corporation  

Allergan Comments on Inamed Statement  

Allergan, Inc. Proposes to Acquire Inamed Corporation for $84 Per Share; Acquisition to Create a World Leading Franchise in High-Growth Medical Aesthetics; Expands Allergan's Position as Premier Specialty Pharmaceutical Company  

Allergan Reports Third Quarter Operating Results and Increases Full Year Earnings Guidance; Pharmaceutical Sales Increased 25 Percent for the Third Quarter; Board of Directors Declares Third Quarter Dividend  

Allergan Announces Revised Date for Quarterly Conference Call  

Allergan Announces Quarterly Conference Call  

Allergan Enters Into Agreement with GlaxoSmithKline to Accelerate BOTOX(R) Development and Commercialization in Japan and China, Co-Promote IMITREX STATdose System(R) and AMERGE(R) in U.S.  

Allergan Receives Positive Opinions for COMBIGAN(TM) from 21 Countries in European Union  

Jeffrey Edwards Promoted to Executive Vice President, Finance and Business Development, Chief Financial Officer as Eric Brandt Resigns to Accept Position as President and Chief Executive Officer of Avanir Pharmaceuticals  

New Formulation of Allergan's ALPHAGAN(R) P Receives U.S. FDA Approval  

Allergan Reports Second Quarter Operating Results and Increases Full Year Earnings Guidance  

Allergan Announces Quarterly Conference Call  

Additional Data From Exploratory Phase II Studies Of Botox® (Botulinum Toxin Type A) As A Preventive Migraine/Headache Treatment To Be Presented At The American Headache Society's Annual Meeting  

Allergan Receives Written Response from FDA on Oral Tazarotene  

Louis J. Lavigne, Jr. Appointed to Allergan's Board of Directors